Tofacitinib treats Mycoplasma Pneumoniae Pneumonia by inhibiting the CXCR4 molecule on the CD4+ T lymphocytes

Kaiwen Wang(Fudan University), Jiangfeng Zhao(Shanghai Jiao Tong University), Hui Du(Shanghai Jiao Tong University), Haiting Yang(Jiading District Central Hospital), Yongqi Zhang(Nanjing Maternity and Child Health Care Hospital), Guo Li(Renji Hospital)
Research Square
April 17, 2025
10.21203/rs.3.rs-6018592/v1
Cited by 0

Related Papers

The DNA sequence of human chromosome 7
|Nature|2003|287
Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis
|Clinical Reviews in Allergy & Immunology|2021|210
Generation and annotation of the DNA sequences of human chromosomes 2 and 4
|Nature|2005|110
CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease
|Lara D. Veeken|2018|60
Effectiveness and safety of tofacitinib<i>versus</i>calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study
|European Respiratory Journal|2025|48